Aquestive Therapeutics, Inc.AQ.STNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -4.28% | +2.92% | +3.99% | +8.47% | +9.27% |
| Gross Profit Growth | +495.16% | +453.81% | +484.56% | -82.06% | +7.68% |
| EBITDA Growth | +9.81% | +0.00% | +8.12% | +5.70% | +3.44% |
| Operating Income Growth | +10.75% | +2.38% | +7.18% | -7.45% | +4.85% |
| Net Income Growth | +16.54% | -9.78% | +4.44% | +5.48% | +9.03% |
| EPS Growth | +16.55% | -9.95% | +4.57% | +5.00% | +8.88% |
| EPS Diluted Growth | +16.55% | -9.95% | +4.59% | +5.66% | +8.88% |
| Weighted Average Shares Growth | -0.00% | -0.28% | -0.40% | +0.26% | +0.29% |
| Weighted Average Shares Diluted Growth | -0.00% | +0.07% | +0.07% | +0.05% | +0.07% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +20.50% | +0.00% | -22.92% | -11.29% | -57.29% |
| Free Cash Flow Growth | +36.72% | -0.97% | -45.24% | -12.99% | -71.07% |
| Receivables Growth | -8.64% | -4.97% | -2.36% | +2.49% | +18.91% |
| Inventory Growth | -2.10% | -0.67% | -0.90% | -1.43% | -3.26% |
| Asset Growth | +10.18% | +5.72% | +7.80% | +6.08% | +5.21% |
| Book Value per Share Growth | +17.29% | +6.82% | +9.94% | +9.64% | +6.03% |
| Debt Growth | -11.44% | +7.82% | +6.02% | -23.43% | -11.02% |
| R&D Expense Growth | +0.00% | +0.00% | +0.00% | +0.00% | -100.00% |
| SG&A Expenses Growth | +0.96% | -100.00% | -100.00% | +0.00% | -100.00% |